Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

The Idiopathic Thrombocytopenic Purpura market is poised for significant expansion through 2032, underpinned by rising disease awareness, improving epidemiological understanding, and a vibrant ...

The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

Gammagard Liquid ERC is a ready-to-use formulation with low IgA content designed to ease administration burden by removing the need to reconstitute.

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions.

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.